ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.
Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady and based in Nijmegen, the Netherlands, ScreenPoint Medical develops and markets innovative machine learning solutions to improve breast cancer screening and diagnosis. With its market-leading AI solution Transpara, ScreenPoint Medical supports radiologists in evaluating mammograms to detect breast cancer and allows them to improve the quality and efficiency of breast cancer screening. Transpara is currently used in over 200 clinics in 25 countries worldwide.
Insight Partners is a US-based venture capital and private equity firm with more than US$30 billion in capital commitments. With its experience and track record of investing in high-growth technology and software companies that drive transformative change in their industries, Insight Partners is ideally situated to support ScreenPoint Medical with its endeavors. Alongside Insight Partners, University Radiology Group, one of the largest providers of sub-specialty radiology and teleradiology services in the United States, participated in the investment round. Existing investors, including ScreenPoint Medical’s founders Siemens Healthineers and Oost NL, will continue to support the company in its further growth and development.
Oaklins’ team in the Netherlands acted as the exclusive advisor to the shareholders and management of ScreenPoint Medical.
ScreenPoint was founded in 2014 as a spin-off from Radboud University Medical Center in Nijmegen, the Netherlands, to develop and bring to market innovative machine learning solutions to improve breast cancer screening and diagnosis. With an exceptional team of specialists in machine learning, image analysis and breast imaging, ScreenPoint developed the market-leading AI solution Transpara for reading mammograms and breast tomosynthesis.
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than US$30 billion in capital commitments. Insight's mission is to find, fund and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all.
Founder and CEO
Talk to the deal team
Martijn de Win
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.Learn more
Dolmen Engineering has been acquired by NIRAS
The private shareholders of Dolmen Engineering have sold the company to NIRAS. The integration will enable the two companies to strengthen their positions within the European life science and food & beverage sectors and offer a fully integrated suite of services.Learn more
Tet has acquired Telia Latvija from Telia Company
Tet, the leading technology and entertainment operator in Latvia, has acquired Telia Latvija – a B2B telecom services provider – from Telia Company in a competitive auction process. The sale price corresponds to an enterprise value of US$11.5 million on a cash and debt free basis, representing a FY 2021 EV/EBITDA multiple of 10.0x.Learn more